Heart failure in elderly patients with chronic obstructive pulmonary disease: reply
We thank the authors for their comments and agree that obstructive sleep apnoea (OSA) could be a risk factor for heart failure in our chronic obstructive pulmonary disease population, just like other known risk factors for heart failure, such as hypertension, diabetes, and atrial fibrillation, which were present in a substantial proportion of our chronic obstructive pulmonary disease patients.
As we mentioned in our discussion paragraph, the outcome panel assessed whether patients had heart failure or chronic obstructive pulmonary disease according to the ESC and GOLD criteria, respectively.
1-3 These criteria are not influenced by the presence of OSA. We therefore disagree with the authors that (possible) concomitant presence of OSA in some of our chronic obstructive pulmonary disease patients could have influenced our prevalence estimates of heart failure. Presence or absence of OSA did not influence the outcome panel's diagnosis of chronic obstructive pulmonary disease or heart failure. The introduction of the term 'pure' chronic obstructive pulmonary disease is therefore incorrect and even somewhat misleading. Association between obesity and obstructive sleep apnoea
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We read with interest the article by Murphy et al.
1 who report a significant association between obesity and fatal and non-fatal cardiovascular events in a large, population-based cohort of middle-aged obese patients compared with normal weight subjects followed for 20 years.
These comments are focused on the role of obstructive sleep apnoea (OSA) as another possible factor contributing to the described high rates of cardiovascular events and mortality in obese patients, an aspect not evaluated in this study. OSA is characterized by periodic reduction or cessation of breathing due to narrowing of the upper airways during sleep. Prevalence surveys estimate that 2% of women and 4% of men of middle age are affected by this syndrome. 2 In patients with untreated severe OSA, a higher incidence of fatal and non-fatal cardiovascular events has been reported in comparison with that observed in untreated patients with mild-moderate OSA, patients treated with continuous positive airway pressure, and healthy subjects. 3 Importantly, it has been estimated that OSA is present in 40% 4 to 90% 5 of obese subjects. Prevalence of OSA is probably rising as a consequence of increasing obesity, obesity being the most important risk factor for OSA. It may be related to changes in upper airway muscle tone, effects of fat deposition on upper airway anatomic structures, and changes in central mechanisms of breathing control. Obesity and OSA share multiple pathophysiological mechanisms such as endothelial dysfunction, insulin resistance, hyperleptinaemia, systemic inflammation, impaired baroreflex, or sympathetic hyperactivity. 6 As a result, OSA may contribute to the presence of cardiovascular events observed in many obese patients.
In contrast, weight loss in OSA patients is associated to reductions in apnoea index, 7 and chronic application of continuous positive airway pressure, the treatment of choice for OSA, reduces body fat and visceral fat accumulation in OSA patients. 8 Therefore, clinicians must be aware to diagnose and treat obese patients for previously undiagnosed OSA, probably helping to reduce the high rates of cardiovascular events related to both conditions. (6MWT) has not yet been proven to be a robust test for identification of the effectiveness of pharmacological treatment because of many even subtle factors influencing the results. They also found that in many studies the exact protocols of the 6MWT were not reported. Especially, practice runs prior to baseline measurements and standardization of patient motivation are urgently needed. In an editorial to that article, Refsgaard 2 even suggested that no encouragement at all should be given to the patients during the test. However, as mentioned in the conclusions, 'the test may be of greater value with more advanced heart failure, where it may function as [a maximal exercise test]'. This can hardly be obtained without encouragement. The American Thoracic Society published guidelines 3 on the 6MWT, where many details such as the length of the corridor, or even the exact wording of the encouragement and its timing were fixed. If all centers abide by those guidelines, or at least report where they did not, results will be much more comparable.
The 'golden standard' of heart failure assessment (at least for survival 4, 5 and indication for transplatation) 6 remains the maximal cardiopulmonary exercise test (CPET) with measurement of peak VO 2 , even though it does not reflect daily activity. Also there is a lack of data on patients being treated with b-blocking agents and/or ICD's, that have proven to prolong survival but do not increase or even decrease VO 2max , and a CPET is not as easily performed as a 6MWT.
